Hofseth BioCare's earnings have been declining at an average annual rate of -3%, while the Biotechs industry saw earnings growing at 23.4% annually. Revenues have been growing at an average rate of 31.6% per year.
Key information
-3.01%
Earnings growth rate
1.84%
EPS growth rate
Biotechs Industry Growth
17.04%
Revenue growth rate
31.55%
Return on equity
-41,903.67%
Net Margin
-52.28%
Next Earnings Update
07 Nov 2025
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Hofseth BioCare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OTCPK:HOFB.F Revenue, expenses and earnings (NOK Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
30 Jun 25
262
-137
97
0
31 Mar 25
274
-129
94
0
31 Dec 24
266
-125
91
0
30 Sep 24
248
-133
84
0
30 Jun 24
230
-121
80
0
31 Mar 24
226
-98
79
0
31 Dec 23
219
-107
76
0
30 Sep 23
205
-93
78
0
30 Jun 23
185
-105
77
0
31 Mar 23
134
-140
76
0
31 Dec 22
120
-137
76
0
30 Sep 22
113
-136
66
0
30 Jun 22
96
-139
64
0
31 Mar 22
102
-135
63
0
31 Dec 21
88
-126
60
0
30 Sep 21
85
-120
44
0
30 Jun 21
79
-115
47
0
31 Mar 21
68
-111
45
0
31 Dec 20
69
-102
43
0
30 Sep 20
57
-104
46
0
30 Jun 20
79
-90
37
0
31 Mar 20
72
-86
36
0
31 Dec 19
68
-89
34
0
30 Sep 19
71
-79
41
0
30 Jun 19
59
-81
42
0
31 Mar 19
61
-83
42
0
31 Dec 18
61
-85
43
0
30 Sep 18
73
-74
36
0
30 Jun 18
84
-66
36
0
31 Mar 18
75
-66
36
0
31 Dec 17
66
-16
34
0
30 Sep 17
43
-28
27
0
30 Jun 17
19
-60
24
0
31 Mar 17
21
-92
21
0
31 Dec 16
20
-147
21
0
30 Sep 16
21
-165
26
0
30 Jun 16
34
-137
28
0
31 Mar 16
32
-109
28
0
31 Dec 15
32
-100
27
0
30 Sep 15
38
-84
22
0
30 Jun 15
23
-82
22
0
31 Mar 15
24
-72
22
0
31 Dec 14
20
-67
22
0
Quality Earnings: HOFB.F is currently unprofitable.
Growing Profit Margin: HOFB.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HOFB.F is unprofitable, and losses have increased over the past 5 years at a rate of 3% per year.
Accelerating Growth: Unable to compare HOFB.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HOFB.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (65.2%).
Return on Equity
High ROE: HOFB.F has a negative Return on Equity (-41903.67%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2025/10/04 19:30
End of Day Share Price
2025/07/07 00:00
Earnings
2025/06/30
Annual Earnings
2024/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hofseth BioCare ASA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.